Want to learn more about the latest in using plasma exchange in ANCA-associated vasculitis? (if you’re a nephrologist, of course you do!)
Check out this rapid summary below!
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
Want to learn more about the latest in using plasma exchange in ANCA-associated vasculitis? (if you’re a nephrologist, of course you do!)
Check out this rapid summary below!
✳️ #TenTweetNephJC ✳️
— Nephrology Jrnl Club (@NephJC) April 8, 2022
👉 where we catch you up on the week's #NephJC chat in 10 tweets
The topic at hand was Plasma Exchange and Vasculitis: the infamous debate of to PLEX or not to PLEX in AAV
Check out this thread to see if you change your mind on this comPLEX topic 👇 pic.twitter.com/PvW0C0O9R9